Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Trial details
- Registry ID
- NCT07397338
- Phase
- Phase 1, Phase 2
The FDA approved Daraxonrasib on 26 Aug 2026.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338 | RVMD | Phase 1, Phase 2 | Recruiting | 2029-05Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-08-26Day | Daraxonrasib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA220910", "applicant_as_listed_by_fda": "REVOLUTION MEDICINES", "brand_names": ["RASONQUE"], "active_ingredients": ["DARAXONRASIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260826", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 16 Nov 2026 · Evidence last checked: 16 Nov 2026 |